Survival Benefit at 7 Years Reported With First-Line Ibrutinib for Chronic Lymphocytic Leukemia
June 5th 2021Median progression-free and overall survival in patients with CLL/SLL receiving ibrutinib in the frontline still not reached at 7-year follow-up, according to data from RESONATE-2 trial reported at the 2021 ASCO Annual Meeting.
Paul M. Barr, MD, Discussed 7-Year Follow-Up Data for Ibrutinib as Frontline Treatment of CLL
June 4th 2021CancerNetwork® sat down with Paul M. Barr, MD, at the 2021 ASCO Annual Meeting to talk about data from RESONATE-2 showing sustained progression-free and overall survival in patients with chronic lymphocytic leukemia being treated with ibrutinib in the frontline setting.
Courtney DiNardo, MD, on Study Methods Evaluating a Doublet, Triplet Regimens in AML
July 8th 2020At the 2020 ASCO Virtual Program, Courtney DiNardo, MD, presented on a study of the combination therapy consisting of ivosenidib plus venetoclax with or without azacytidine patients with IDH1-mutated acute myeloid leukemia.
CARTITUDE-1 Study Results Show Promise for Patients with Relapsed/Refractory Multiple Myeloma
June 13th 2020Jesus G. Berdeja, MD, of the Sarah Cannon Research Institute discussed the CARTITUDE-1 study that examined CAR-T cell therapy to treat patients with relapsed/refractory multiple myeloma presented at the 2020 ASCO Virtual Scientific Program.
Parameswaran Hari, MD, MRCP, Discusses Lenalidomide Maintenance Outcomes in Multiple Myeloma
June 5th 2020Parameswaran Hari, MD, MRCP, discussed the progression-free survival of patients who stopped versus continued lenalidomide maintenance therapy to treat multiple myeloma from a follow-up trial presented at the 2020 ASCO Virtual Scientific Program.
KTE-X19 Proves Comparable to Current Therapies in Treating High-Risk MCL
May 31st 2020When compared to currently approved therapies, KTE-X19 demonstrated comparable pharmacologic and clinical outcomes in patients with high-risk MCL characteristics versus lower-risk characteristics defined by tumor protein TP53 mutation or high Ki-67 proliferation index.
Off-the-Shelf CAR T-Cell Therapy Shows Promise in Relapsed/Refractory B-Cell Lymphomas
May 30th 2020The allogeneic CAR-T cell therapy ALLO-501, paired with the monoclonal antibody ALLO-647, demonstrated clinical responses and manageable toxicity in patients with pretreated large B-cell and follicular lymphomas in the Phase I ALPHA trial.
Pembrolizumab Shows Superior PFS in Relapsed/Refractory Classical Hodgkin Lymphoma
May 30th 2020Results of KEYNOTE-204 supports pembrolizumab as new standard of care for patients with classical Hodgkin Lymphoma who have relapsed after autologous stem cell transplant or are ineligible for autologous stem cell transplant.
Addition of Selinexor to Bortezomib, Dexamethasone Improves Responses in Myeloma
May 29th 2020The addition of selinexor, a selective inhibitor of nuclear export, to bortezomib and dexamethasone improved progression-free survival across all subgroups in a study of pretreated patients with multiple myeloma.
Zanubrutinib Appears to be Safe, Effective for Waldenström Macroglobulinemia
May 29th 2020According to the largest phase III trial examining BTK inhibitors for patients with Waldenström macroglobulinemia, zanubrutinib appears to be associated with higher complete response or very good partial response, as well as clinically meaningful advantages in safety and tolerability compared to ibrutinib.
Carfilzomib Triplet Fails to Induce Superior PFS in Newly Diagnosed Multiple Myeloma
May 29th 2020Carfilzomib combined with lenalidomide and dexamethasone failed to improve progression-free survival, compared with the current standard of care triplet of bortezomib, lenalidomide, and dexamethasone, in patients with newly diagnosed multiple myeloma.